OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 21:22 UTC. Every row links to its source record.

AMER1 APC membrane recruitment protein 1

ENSG00000184675 · protein coding · Open Targets profile

Regulator of the canonical Wnt signaling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane and interacting with key regulators of the canonical Wnt signaling pathway, such as components of the beta-catenin destruction complex. Acts both as a positive and negative regulator of the Wnt signaling pathway, depending on the context: acts as a positive regulator by promoting LRP6 phosphorylation. Also acts as a negative regulator by acting as a scaffold protein for the beta-catenin destruction complex and promoting stabilization of Axin at the cell membrane. Promotes CTNNB1 ubiquitination and degradation. Involved in kidney development. {ECO:0000269|PubMed:17510365, ECO:0000269|PubMed:17925383, ECO:0000269|PubMed:19416806, ECO:0000269|PubMed:21304492, ECO:0000269|PubMed:21498506}.

In 13 of 15 cancers, the evidence for AMER1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.81colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.70colorectal cancercolorectal cancercolorectal cancer: germline 0.77chronic myeloid leukemiachronic myeloid leukemiachronic myeloid leukemia: somatic 0.46NephroblastomaNephroblastomaNephroblastoma: somatic 0.32kidney Wilms tumorkidney Wilms tumorkidney Wilms tumor: somatic 0.61rectum adenocarcinomarectum adenocarcinomarectum adenocarcinoma: somatic 0.61nodular malignant melanomanodular malignant melanomanodular malignant melanoma: somatic 0.61cecum adenocarcinomacecum adenocarcinomacecum adenocarcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61superficial spreading melanomasuperficial spreading melanomasuperficial spreading melanoma: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61kidney neoplasmkidney neoplasmhepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody
GO CC high conf, UniProt loc med conf, Human Protein Atlas loc
PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.30173999071121216 (upper bound 0.4582900106906891). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of AMER1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of AMER1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.